Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial

Paul McNally, Karen Lester, Rachel Cregan, Basil Elnazir, Thara Persaud, David Rea, Eilish Twomey, Mike Williamson, Des W Cox, Barry Linnane, Siobhan McGrane, Laura Kirwan, Paul O’Regan, Merlijn Bonte, Punit Makani, Daan Caudri, Jonathan D Dodd, Edward F McKone, Clare Saunders, Thomas Semple, Jane C Davies, Harm A W M Tiddens, Unknown, Colin Lewis, Aisling McQuaid, Aideen Lambe, David Reidy, Jennifer Matthews, Kevin Brannigan, Elizabeth Shaw, Jorien van de Puttelaar, Aleksandra Kusiak, Ava Harte, Sarah Badar, Brenda Grogan, Magdalena Mulligan, Mary Abkir, Chris Short, Tatenda Nyatoro, Benat Broderick, Caroline Heffernan, Carolyn Thornton

Open source

DOI: 10.1093/annalsats/aaoag021
Published: 2026-02-02
Container: Annals of the American Thoracic Society
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/annalsats/aaoag021,
  title = {Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial},
  author = {Paul McNally and Karen Lester and Rachel Cregan and Basil Elnazir and Thara Persaud and David Rea and Eilish Twomey and Mike Williamson and Des W Cox and Barry Linnane and Siobhan McGrane and Laura Kirwan and Paul O’Regan and Merlijn Bonte and Punit Makani and Daan Caudri and Jonathan D Dodd and Edward F McKone and Clare Saunders and Thomas Semple and Jane C Davies and Harm A W M Tiddens and Unknown and Colin Lewis and Aisling McQuaid and Aideen Lambe and David Reidy and Jennifer Matthews and Kevin Brannigan and Elizabeth Shaw and Jorien van de Puttelaar and Aleksandra Kusiak and Ava Harte and Sarah Badar and Brenda Grogan and Magdalena Mulligan and Mary Abkir and Chris Short and Tatenda Nyatoro and Benat Broderick and Caroline Heffernan and Carolyn Thornton},
  year = {2026},
  journal = {Annals of the American Thoracic Society},
  doi = {10.1093/annalsats/aaoag021},
  url = {https://doi.org/10.1093/annalsats/aaoag021}
}

RIS

TY  - JOUR
TI  - Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial
AU  - Paul McNally
AU  - Karen Lester
AU  - Rachel Cregan
AU  - Basil Elnazir
AU  - Thara Persaud
AU  - David Rea
AU  - Eilish Twomey
AU  - Mike Williamson
AU  - Des W Cox
AU  - Barry Linnane
AU  - Siobhan McGrane
AU  - Laura Kirwan
AU  - Paul O’Regan
AU  - Merlijn Bonte
AU  - Punit Makani
AU  - Daan Caudri
AU  - Jonathan D Dodd
AU  - Edward F McKone
AU  - Clare Saunders
AU  - Thomas Semple
AU  - Jane C Davies
AU  - Harm A W M Tiddens
AU  - Unknown
AU  - Colin Lewis
AU  - Aisling McQuaid
AU  - Aideen Lambe
AU  - David Reidy
AU  - Jennifer Matthews
AU  - Kevin Brannigan
AU  - Elizabeth Shaw
AU  - Jorien van de Puttelaar
AU  - Aleksandra Kusiak
AU  - Ava Harte
AU  - Sarah Badar
AU  - Brenda Grogan
AU  - Magdalena Mulligan
AU  - Mary Abkir
AU  - Chris Short
AU  - Tatenda Nyatoro
AU  - Benat Broderick
AU  - Caroline Heffernan
AU  - Carolyn Thornton
PY  - 2026
JO  - Annals of the American Thoracic Society
DO  - 10.1093/annalsats/aaoag021
UR  - https://doi.org/10.1093/annalsats/aaoag021
ER  -

APA

McNally, P., Lester, K., Cregan, R., Elnazir, B., Persaud, T., Rea, D., Twomey, E., Williamson, M., Cox, D. W., Linnane, B., McGrane, S., Kirwan, L., O’Regan, P., Bonte, M., Makani, P., Caudri, D., Dodd, J. D., McKone, E. F., Saunders, C., Semple, T., Davies, J. C., Tiddens, H. A. W. M., Unknown, Lewis, C., McQuaid, A., Lambe, A., Reidy, D., Matthews, J., Brannigan, K., Shaw, E., Puttelaar, J. V. D., Kusiak, A., Harte, A., Badar, S., Grogan, B., Mulligan, M., Abkir, M., Short, C., Nyatoro, T., Broderick, B., Heffernan, C., & Thornton, C. (2026). Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial. Annals of the American Thoracic Society. https://doi.org/10.1093/annalsats/aaoag021

Source records

crossref · retrieved 2026-09-26T18:00:01.073Z